That is great news for the companies looking to get into the market and companies already in the cannabinoid market, but what about our company specifically?
I guess what I'm saying is, I'm looking at this from the point of view that there is a def. going to be a great market for these products very soon, a market we have never seen before in the history of this country. Basically, I'm trying to look at it as if CBIS was just any ol' developmental stage pharm. company planning to make ordinary generic drugs that nobody has a problem with other than if they work and they're safe. From that point of view, I'm not asking if their will be a market for this stuff and if pharm. companies can be successful in this market, but whether or not CBIS can successfully manage the risk vs. reward of the FDA drug approval process in general. Although I don't have tons of experience buying biotech stock, it seems to me that by far the most trouble pharm. companies have is getting their drug approved in the first place.
And to that, what is CBIS doing as a dev. company looking to get into the medicinal cannabinoid market to cover their a-holes in case this skin cancer treatment doesn't work out? Just selling pot to dispensaries is not enough to justify the stock price now or in the future, and riding your entire development line on curing skin cancer is too risky, even if they don't really have the money right now to explore other avenues simultaneously. I dunno, is this making sense?
News 
Market Data 
Discover 
AI
